Dates for the European Rare Disease Organisation, EURORDIS, Summer School for Patient Advocates 2023 now announced: June 19-23, 2023, Barcelona

The EURORDIS Summer School on Medicines Research & Development consists of a one week of face-to-face training, held in June in Barcelona. Free e-learning modules are also available on demand. The EURORDIS Summer School aims to provide rare disease patient advocates with the knowledge and skills needed to become experts in medicines research and development. […]

Dates for the European Rare Disease Organisation, EURORDIS, Summer School for Patient Advocates 2023 now announced: June 19-23, 2023, Barcelona Read Post »

How do clinical trials work? Here is a video by top pulmonary hypertension medical expert Vallerie McLaughlin that explains it all! A phaware global initiative

Vallerie McLaughlin, MD from Michigan Medicine’s Cardiovascular Center, discusses the basics of clinical trials in this very informative video care of phaware. Check out the video on the phaware YouTube channel at this link Learn more about phaware at this link

How do clinical trials work? Here is a video by top pulmonary hypertension medical expert Vallerie McLaughlin that explains it all! A phaware global initiative Read Post »

PAHSSc, Turkish pulmonary hypertension association, interview with Shaun Clayton, Director of Membership Support at the Pulmonary Hypertension Association (PHA UK)

Could you kindly tell us something about yourself? I am the Director of Membership Support at the Pulmonary Hypertension Association (PHA UK), where I have worked for the last ten years. As part of a small yet dynamic team, my role is to ensure the charity is supporting its membership in the best possible way.

PAHSSc, Turkish pulmonary hypertension association, interview with Shaun Clayton, Director of Membership Support at the Pulmonary Hypertension Association (PHA UK) Read Post »

EURORDIS, the European Rare Disease Organisation, and EFPIA, the European Federation of Pharmaceutical Industries and Associations issue Joint Statement on how to improve patient access to medicines

The EURORDIS-EFPIA Joint Statement on proposals to improve patient access to medicines was published on June 15 2022. As the EURORDIS-EFPIA press release reads “This is the first time that EURORDIS-Rare Diseases Europe, as a patient organisation, has come together with the pharmaceutical industry’s European organisation in such a structured dialogue. Discussions focused on how

EURORDIS, the European Rare Disease Organisation, and EFPIA, the European Federation of Pharmaceutical Industries and Associations issue Joint Statement on how to improve patient access to medicines Read Post »

June 9, 2022: Patient engagement in drug development, a live symposium organised by admedicum

On June 9th 2022, patient engagement experts at admedicum organized a live event in collaboration with HollandBIO and INSMED Pharmaceuticals, Inc. in Utrecht, with over 70 attendees and distinguished speakers from patient organisations, healthcare, regulatory and industry. The theme was “Patient engagement in 2030: how can patient engagement contribute towards building a new ecosystem for

June 9, 2022: Patient engagement in drug development, a live symposium organised by admedicum Read Post »

PAHSSc, Turkish pulmonary hypertension association, interview with Noriko Murakami, President of PHA Japan, mother of a young patient who had a lung transplant from a living donor

Noriko Murakami is the President of PHA Japan and the mother of Yukiko, a young PH patient who had a lung transplant surgery from a live donor. The PAHSSc is grateful to Mrs. Noriko Murakami for having agreed to contribute to its magazine Nefes (The Breath ) with insights on lung transplantation from a live

PAHSSc, Turkish pulmonary hypertension association, interview with Noriko Murakami, President of PHA Japan, mother of a young patient who had a lung transplant from a living donor Read Post »

PAHSSc, Turkish pulmonary hypertension association, interview with Aryeh Copperman, the CEO of the PH Israel Patient Association and husband of a pulmonary arterial hypertension patient 

Would you kindly give us some information about yourself? My name is Aryeh Copperman, I am the CEO since 2005 of Isreal’s pulmonary hypertension association. I have a BA in Accounting and information systems, and Masters Degree in Public Health, from the Hebrew University in Jerusalem. I am married with 4 children. My wife has

PAHSSc, Turkish pulmonary hypertension association, interview with Aryeh Copperman, the CEO of the PH Israel Patient Association and husband of a pulmonary arterial hypertension patient  Read Post »

PHA Europe “Call to Action on the unmet needs of patients with pulmonary hypertension” launch event in the European Parliament, April 2022

PHA Europe organized an event in the EU Parliament on April 26, 2022 for the launch of its “Call to Action on the unmet needs of patients with pulmonary hypertension”. The event was hosted by MEP Istvan Ujhelyi (Hungary) and chaired by Prof. Marc Humbert (ERS President). The Call to Action is a revisit of

PHA Europe “Call to Action on the unmet needs of patients with pulmonary hypertension” launch event in the European Parliament, April 2022 Read Post »

European Respiratory Society (ERS) web event on “Living with rare respiratory diseases through the COVID-19 pandemic”

This live online discussion organised by the European Respiratory Society (ERS) was held on March 23, 2022, and focused on the experiences and learnings of specialists and patients in the fields of idiopathic pulmonary fibrosis, pulmonary hypertension, cystic fibrosis and bronchiectasis ,since the emergence of COVID-19. ERS President Elect Professor Marc Humbert and European Respiratory

European Respiratory Society (ERS) web event on “Living with rare respiratory diseases through the COVID-19 pandemic” Read Post »

“The Added Value of Patient Engagement in Early Dialogue at the European Medicines Agency (EMA): Scientific Advice as a Case Study”, Frontiers in Medicine

  ABSTRACT The European Medicines Agency provides Scientific Advice to medicines developers and patient input has been an integral part of this process for many years. As end users of medicines, patients bring their perspectives to many different processes along EMA’s regulatory pathway, complementing the scientific expertise. While the value of including patients has been

“The Added Value of Patient Engagement in Early Dialogue at the European Medicines Agency (EMA): Scientific Advice as a Case Study”, Frontiers in Medicine Read Post »

The European Medicines Agency (EMA) updates its engagement framework with patients, consumers and their organisations

The European Medicines Agency (EMA) engagement framework aims to Facilitate participation of patients and consumers in regulatory activities all along the entire lifecycle of medicines; Foster the development of guidance and methodologies to increase collection and use of relevant patient experience data in the context of regulatory decision making; Ensure that patients, consumers and their

The European Medicines Agency (EMA) updates its engagement framework with patients, consumers and their organisations Read Post »

Live web event on “Improving lung health through the future European Health Data Space”, MEP Lung Health Group

On February 8 2022 the MEP Lung Health Group organised a virtual event on “Improving lung health through the future European Health Data Space”, hosted by the Group members Co-Chair MEPs Manuel Pizarro (S&D – Portugal) and Sara Cerdas (S&D – Portugal). Panelists included EU policy makers, digital health experts, healthcare professionals, and patient representatives

Live web event on “Improving lung health through the future European Health Data Space”, MEP Lung Health Group Read Post »

European Patients’ Academy on Therapeutic Innovation (EUPATI), a patient-led initiative to enhance knowledge of medicine R & D processes

The European Patients’ Academy on Therapeutic Innovation (EUPATI) is a patient-led partnership working across stakeholders to enhance patient engagement, registered as an independent non-profit Foundation in the Netherlands. It announced today an important milestone for their “Toolbox”: 5 million unique users since its launch in 2016. Explore the EUPATI Toolbox to learn more about medicine

European Patients’ Academy on Therapeutic Innovation (EUPATI), a patient-led initiative to enhance knowledge of medicine R & D processes Read Post »

The EU Clinical Trials Regulation came into force 31st of January 2022

The European Union (EU) pharmaceutical legislation known as the Clinical Trials Regulation comes into force today, the 31st of January 2022. It aims to ensure the EU offers an attractive and favourable environment for carrying out clinical research on a large scale, with high standards of public transparency and safety for clinical trial participants. Prior to

The EU Clinical Trials Regulation came into force 31st of January 2022 Read Post »

“What’s next for digital health after COVID-19?”, MedTech Views

What’s next for digital health after COVID-19? Here is an interesting article from MedTechViews by Naveed Khan, Director of Commercial and Business Development/Digital Health at Biotronik. The author says there is no doubt the pandemic has accelerated digital health but, for new innovations to truly work for both physicians and patients, help is needed to

“What’s next for digital health after COVID-19?”, MedTech Views Read Post »

“Accelerating Clinical Trials in the EU for better clinical trials that address patients’ needs”, a joint initiative of the EU Commission, the European Medicines Agency Heads of Medicines Agencies (HMA)

On January 2022 a new initiative launched by the European Commission, the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) aims to transform how clinical trials are initiated, designed, and run. This initiative, called “Accelerating Clinical Trials in the EU for better clinical trials that address patients’ needs“, aims to further develop

“Accelerating Clinical Trials in the EU for better clinical trials that address patients’ needs”, a joint initiative of the EU Commission, the European Medicines Agency Heads of Medicines Agencies (HMA) Read Post »

Interview with Hans Dieter Kulla, the President of The German PH association PHeV for “Nefes” (1st issue of the Turkish pulmonary hypertension association PAHSSc magazine) 

Could you kindly tell us something about yourself? I have been president of the German PHeV since 2012. My input and the one of all others is voluntary! I am not a patient and I contribute to our organization in a “strategical” way. We have regional groups in nearly every region of Germany. Our group

Interview with Hans Dieter Kulla, the President of The German PH association PHeV for “Nefes” (1st issue of the Turkish pulmonary hypertension association PAHSSc magazine)  Read Post »

First-ever UN Resolution addresses the challenges of the 300 Million Persons Living with a Rare Disease

On December 16, 2021 the UN General Assembly formally adopted Resolution A/RES/76/132 recognising the over 300 million Persons Living with a Rare Disease (PLWRD) worldwide and their families. The Resolution focuses on the importance of non-discrimination and advances key pillars of the UN Sustainable Development Goals (SDGs), including access to education and decent work, reducing

First-ever UN Resolution addresses the challenges of the 300 Million Persons Living with a Rare Disease Read Post »

In his inaugural speech Prof. Marc Humbert, newly elected President of the European Respiratory Society (ERS), makes the case for patient-centric medicine

Congratulations to Prof. Marc Humbert for his election as President of the European Respiratory Society (ERS). Prof. Humbert has published more than 700 peer-reviewed articles, mostly in the field of pulmonary hypertension, and is widely considered one of the world TLs in pulmonary hypertension. In his inaugural speech Prof. Humbert said he would continue to

In his inaugural speech Prof. Marc Humbert, newly elected President of the European Respiratory Society (ERS), makes the case for patient-centric medicine Read Post »

“How-to guides” for patient engagement in key phases of medicines development, by the PFMD

Patient Focused Medicines Development (PFMD) is a not-for-profit collaborative initiative benefiting patients and health stakeholders by designing a patient-centred healthcare system with patients and all stakeholders. The importance of patient engagement (PE) across the medicines development continuum is widely acknowledged across diverse health stakeholder groups, including health authorities; however, the practical applications of how to

“How-to guides” for patient engagement in key phases of medicines development, by the PFMD Read Post »

TRANSLATE »
Scroll to Top